Outputs (8)

Development and characterisation of a new patient-derived xenograft model of AR-negative metastatic castration-resistant prostate cancer (2024)
Journal Article

As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE)... Read More about Development and characterisation of a new patient-derived xenograft model of AR-negative metastatic castration-resistant prostate cancer.

Suppression of Bcl3 disrupts viability of breast cancer cells through both p53-dependent and p53-independent mechanisms via loss of NF-κB signalling (2024)
Journal Article

The NF-κB co-factor Bcl3 is a proto-oncogene that promotes breast cancer proliferation, metastasis and therapeutic resistance, yet its role in breast cancer cell survival is unclear. Here, we sought to determine the effect of Bcl3 suppression alone o... Read More about Suppression of Bcl3 disrupts viability of breast cancer cells through both p53-dependent and p53-independent mechanisms via loss of NF-κB signalling.

PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate (2023)
Journal Article

The PIP3/PI3K network is a central regulator of metabolism and is frequently activated in cancer, commonly by loss of the PIP3/PI(3,4)P2 phosphatase, PTEN. Despite huge research investment, the drivers of the PI3K network in normal tissues and how th... Read More about PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate.

The discovery of a novel antimetastatic Bcl3 inhibitor (2021)
Journal Article

The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options are limited and often associated wit... Read More about The discovery of a novel antimetastatic Bcl3 inhibitor.

The PTEN conundrum: How to target PTEN-deficient prostate cancer (2020)
Journal Article

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to advanced prostate cancer progression and poor clinical outcome. Accordingly, se... Read More about The PTEN conundrum: How to target PTEN-deficient prostate cancer.

Biodistribution PET/CT study of Hemoglobin-DFO-89Zr complex in healthy and lung tumor-bearing mice (2020)
Journal Article

Proteins, as a major component of organisms, are considered the preferred biomaterials for drug delivery vehicles. Hemoglobin (Hb) has been recently rediscovered as a potential drug carrier, but its use for biomedical applications still lacks extensi... Read More about Biodistribution PET/CT study of Hemoglobin-DFO-89Zr complex in healthy and lung tumor-bearing mice.

Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42 (2020)
Journal Article

A key challenge in the implementation of anti-metastatics as cancer therapies is the multi-modal nature of cell migration, which allows tumour cells to evade the targeted inhibition of specific cell motility pathways. The nuclear factor-kappaB (NF-κB... Read More about Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42.

β‐Bisabolene, a sesquiterpene from the essential oil extract of opoponax (Commiphora guidottii), exhibits cytotoxicity in breast cancer cell lines (2015)
Journal Article

The essential oils from Commiphora species have for centuries been recognized to possess medicinal properties. Here, we performed gas chromatography-mass spectrometry on the essential oil from opoponax (Commiphora guidotti) and identified bisabolene... Read More about β‐Bisabolene, a sesquiterpene from the essential oil extract of opoponax (Commiphora guidottii), exhibits cytotoxicity in breast cancer cell lines.